1. Thapa, R., Bajimaya, S., Paudyal, G., Khanal, S., Tan, S. et al. (2017) Prevalence, pattern and risk factors of retinal vein occlusion in an elderly population in Nepal: the Bhaktapur retina study. Bmc Ophthalmol. 17, 162.
2. Cheung, N., Klein, R., Wang, J. J., Cotch, M. F., Islam, A. F. et al. (2008) Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci. 49, 4297-4302.
3. Ponto, K. A., Elbaz, H., Peto, T., Laubert-Reh, D., Binder, H. et al. (2015) Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J Thromb Haemost. 13, 1254-1263.
4. Adelman, R. A., Parnes, A. J., Bopp, S., Saad, O. I., Ducournau, D. (2015) Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study. Biomed Res Int. 2015, 870987.
5. Mitry, D., Bunce, C., Charteris, D. (2013) Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst RevD9510.
6. Demir, M., Oba, E., Guven, D., Acar, Z., Cinar, S. (2014) Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion. Int J Clin Pharm. 36, 438-442.
7. Blanc, J., Deschasse, C., Kodjikian, L., Dot, C., Bron, A. M. et al. (2018) Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol. 256, 1441-1448.
8. Campochiaro, P. A., Sophie, R., Pearlman, J., Brown, D. M., Boyer, D. S. et al. (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 121, 209-219.
9. Konidaris, V. E., Tsaousis, K. T., Anzidei, R., de la Mata, G., Brent, A. J. (2018) Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion. Ophthalmol Ther. 7, 387-395.
10. Yang, C. S., Liu, J. H., Chung, Y. C., Chou, Y. B., Hung, K. H. (2015) Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion. J Ocul Pharmacol Ther. 31, 179-185.
11. Konidaris, V. E., Tsaousis, K. T., Anzidei, R., de la Mata, G., Brent, A. J. (2018) Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion. Ophthalmol Ther. 7, 387-395.
12. Hsueh, J., Wai, K. M., Conti, F. F., Conti, T. F., Singh, R. P. (2018) Impact of Time to Anti-Vascular Endothelial Growth Factor Intervention on Visual Outcomes for Patients Diagnosed With Retinal Vein Occlusion. Ophthalmic Surg Lasers Imaging Retina. 49, 832-837.
13. Ehlken, C., Helms, M., Bohringer, D., Agostini, H. T., Stahl, A. (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 12, 13-20.
14. Ohta, S. (2014) Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. Pharmacol Ther. 144, 1-11.
15. Qi, L. S., Yao, L., Liu, W., Duan, W. X., Wang, B. et al. (2015) Sirtuin Type 1 Mediates the Retinal Protective Effect of Hydrogen-Rich Saline Against Light-Induced Damage in Rats. Invest Ophthalmol Vis Sci. 56, 8268-8279.
16. Yan, W. M., Chen, T., Wang, X. C., Qi, L. S., Zhao, G. H. et al. (2017) The reason for the amelioration of N-methyl-N-nitrosourea-induced retinitis pigmentosa in rats by hydrogen-rich saline. Int J Ophthalmol. 10, 1495-1503.
17. Yan, W. M., Zhang, L., Chen, T., Zhao, G. H., Long, P. et al. (2017) Effects of hydrogen-rich saline on endotoxin-induced uveitis. Med Gas Res. 7, 9-18.
18. McCulloch, D. L., Marmor, M. F., Brigell, M. G., Hamilton, R., Holder, G. E. et al. (2015) ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol. 130, 1-12.
19. Jonas, J. B., Xu, L., Wang, Y. X. (2009) The Beijing Eye Study. Acta Ophthalmol. 87, 247-261.
20. Ham, D. I., Chang, K., Chung, H. (1997) Preretinal neovascularization induced by experimental retinal vein occlusion in albino rats. Korean J Ophthalmol. 11, 60-64.
21. Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L. et al. (2009) PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther. 25, 519-530.
22. Tamura, M. (2001) Neovascularization in experimental retinal venous obstruction in rabbits. Jpn J Ophthalmol. 45, 144-150.
23. El-Dessouky, E. S., Moshfeghi, A. A., Peyman, G. A., Yoneya, S., Mori, K. et al. (2001) Toxicity of the photosensitizer NPe6 following intravitreal injection. Ophthalmic Surg Lasers. 32, 316-321.
24. Takei, K., Sato, T., Nonoyama, T., Miyauchi, T., Goto, K. et al. (1993) A new model of transient complete obstruction of retinal vessels induced by endothelin-1 injection into the posterior vitreous body in rabbits. Graefes Arch Clin Exp Ophthalmol. 231, 476-481.
25. Wallow, I. H., Danis, R. P., Bindley, C., Neider, M. (1988) Cystoid macular degeneration in experimental branch retinal vein occlusion. Ophthalmology. 95, 1371-1379.
26. Ieki, Y., Nishiwaki, H., Miura, S., Yamashiro, K., Nishijima, K. et al. (2002) Experimental macular edema induced by macular venule occlusion in monkey. Curr Eye Res. 25, 123-131.
27. Ohta, S. (2014) Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. Pharmacol Ther. 144, 1-11.
28. Johnson, D. A., Johnson, J. A. (2015) Nrf2--a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med. 88, 253-267.
29. Sauer, H., Wartenberg, M., Hescheler, J. (2001) Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem. 11, 173-186.
30. Ohta, S. (2011) Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications. Curr Pharm Des. 17, 2241-2252.
31. Fontanari, P., Badier, M., Guillot, C., Tomei, C., Burnet, H. et al. (2000) Changes in maximal performance of inspiratory and skeletal muscles during and after the 7.1-MPa Hydra 10 record human dive. Eur J Appl Physiol. 81, 325-328.
32. Yao, J., Chen, Z., Yang, Q., Liu, X., Chen, X. et al. (2013) Proteomic analysis of aqueous humor from patients with branch retinal vein occlusion-induced macular edema. Int J Mol Med. 32, 1421-1434.
33. Kida, T., Flammer, J., Oku, H., Morishita, S., Fukumoto, M. et al. (2016) Suppressed endothelin-1 by anti-VEGF therapy is important for patients with BRVO-related macular edema to improve their vision. Epma J. 7, 18.
34. Campochiaro, P. A., Heier, J. S., Feiner, L., Gray, S., Saroj, N. et al. (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 117, 1102-1112.
35. Pielen, A., Feltgen, N., Isserstedt, C., Callizo, J., Junker, B. et al. (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. Plos One. 8, e78538.
36. Huang, Z. L., Lin, K. H., Lee, Y. C., Sheu, M. M., Tsai, R. K. (2010) Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome. Ophthalmologica. 224, 86-89.
37. Vertes, D., Snyers, B., De Potter, P. (2010) Cytomegalovirus retinitis after low-dose intravitreous triamcinolone acetonide in an immunocompetent patient: a warning for the widespread use of intravitreous corticosteroids. Int Ophthalmol. 30, 595-597.
38. Romero-Aroca, P. (2013) Current status in diabetic macular edema treatments. World J Diabetes. 4, 165-169.
39. Campa, C., Alivernini, G., Bolletta, E., Parodi, M. B., Perri, P. (2016) Anti-VEGF Therapy for Retinal Vein Occlusions. Curr Drug Targets. 17, 328-336.
40. Wu, J., Wang, R., Yang, D., Tang, W., Chen, Z. et al. (2018) Hydrogen postconditioning promotes survival of rat retinal ganglion cells against ischemia/reperfusion injury through the PI3K/Akt pathway. Biochem Biophys Res Commun. 495, 2462-2468.